Consolidated Statement of Operations and Comprehensive Loss (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2021	Sep. 30, 2020	Sep. 30, 2021	Sep. 30, 2020
Revenues:
Total Revenues	$ 33	$ 36	$ 85	$ 121
Costs and Expenses:
Production costs	157	204	674	608
Research and development	2,006	1,102	4,749	3,445
General and administrative	1,799	2,085	6,055	6,070
Total Costs and Expenses	(3,962)	3,391	11,478	10,123
Operating loss	(3,929)	(3,355)	(11,393)	(10,002)
Interest and other income, net	(20)	69	100	131
Interest expense and other finance costs		(51)	(67)	(617)
Extinguishment of financing obligation and note payable			(2,701)	142
Gain on sale of fixed assets			216
Redeemable warrants valuation adjustment	51	31	22	(120)
Gain from sale of Income tax operating losses	72		542
Net Loss	(3,826)	(3,306)	(13,281)	(10,466)
Other comprehensive (loss), net of tax
Reclassification adjustment for realized investment loss	101		126
Change in unrealized loss on marketable securities available for sale	(104)	(75)	(329)	(12)
Comprehensive loss	$ (3,829)	$ (3,381)	$ (13,484)	$ (10,478)
Basic and diluted loss per share	$ (0.08)	$ (0.08)	$ (0.28)	$ (0.36)
Weighted average shares outstanding basic and diluted	47,846,074	38,907,546	47,156,158	28,826,283
Clinical Treatment Programs US [Member]
Revenues:
Total Revenues	$ 33	$ 27	$ 85	$ 110
Clinical Treatment Programs Europe [Member]
Revenues:
Total Revenues		$ 9		$ 11